Clinically relevant drug interactions with rifampicin - An update;Klinisch relevante interaktionen mit rifampicin - Ein update

Chemotherapie Journal

Volumn 20, Issue 1, 2011, Pages 18-24

  Kämmerer, Wolfgang ^a  

^a DR HORST SCHMIDT KLINIKEN   (Germany)

Author keywords

Clinically relevant; Drug interactions; Pharmacokinetic; Rifampicin

Indexed keywords

RIFAMPICIN;

ANTIMICROBIAL ACTIVITY; DRUG EFFICACY; DRUG METABOLISM; DRUG POTENCY; DRUG TRANSPORT; DRUG WITHDRAWAL; HUMAN; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; NONHUMAN; REVIEW; TUBERCULOSIS;

EID: 79951795012     PISSN: 09406735     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (36)

1. Abajo FJ. Phenytoin interaction with rifampicin. BMJ 1988;297:1048.
2. Ament PW, Bertoline JG, et al. Clinically significant drug interactions. Am Fam Physician 2000;61:1745-54. (Pubitemid 30193572)
3. Bolt HM. Rifampicin, a keystone inducer of drug metabolism: from Herbert Remmers's pioneering ideas to modern concepts. Drug Metabol Rev 2004;36:497-509. (Pubitemid 39456439)
4. Bolton AE, Peng B, Hubert M. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53:102-6. (Pubitemid 38186987)
5. Borcherding SM, Baciewicz AM, et al. Update on rifampin drug interactions. Arch Intern Med 1992;152:711-6.
6. Chen Y, Ferguson SS, Negishi M. Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J Pharmacol Exp Ther 2004;308:495-501. (Pubitemid 38134210)
7. Datenbank: Micromedex @ Healthcare Series: Drugdex @ System. Stand 30.10.2010.
8. Fachinformationen, Stand 09/2010.
9. Finch CK, Chrisman CR, et al. Rifampin and rifabutin drug interactions - An update. Arch Intern Med 2002;162:985-92. (Pubitemid 34492526)
10. Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J Biol Chem 2001;276:14581-7.
11. Glaeser H, Drescher S, Eichelbaum M. Influence of rifampicin on the expression and function of human intestinal cytochrome P450 enzymes. Br J Clin Pharmacol 2005;59:199-206. (Pubitemid 40208856)
12. Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999;104:147-53.
13. Internet: Cytochrome P450 Drug Interaction Table: ttp://medicine. iupuLedujflockhart
14. Internet: www.kardiolab.ch/CYP450-2JSI.html
15. Internet: www.mediq.ch
16. Jiezhong C, Raymond K. Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor. Ann Clin Microbiol Antimicrob 2006;5:3.
17. Jung YJ, Koh Y, Hong SB, Chung JW, et al. Effect of vancomycin plus rifampicin in the treatment of nosocomial methicillin-resistant Staphylococcus aureus pneumonia. Crit Care Med 2010;38:175-80.
18. Kämmerer W. Pharmakokinetische Interaktionen von Tyrosinkinase- hemmern. Internistische Praxis 2009;49:839-52.
19. Kämmerer W. Klinisch relevante pharmakokinetische Interaktionen von und mit Zytostatika. Arzneimitteltherapie 2008;26:51-61. (Pubitemid 351299773)
20. Kivistö KT, Villikka K, et al. Tamoxifen and toremifene concentrations in plasma are greatly decreased by rifampin. Clin Pharmacol Ther 1998;64:648-54. (Pubitemid 29011384)
21. Kolars JC, Schmiedlin-Ren P, Schuetz JD. Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 1992;90:1871-8.
22. Kyrklund C, Backman JT, Kivisto KT. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 2000;68:592-7. (Pubitemid 32059984)
23. Lee CR, Thrasher KA. Difficulties in anticoagulation management during co-administration of warfarin and rifampin. Pharmacotherapy 2001;21:1240-6. (Pubitemid 32939098)
24. Lehmann JM, McKee DD, Watson MA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J Clin Invest 1998;102:1016-23.
25. Maartens G, Decloedt E, Cohen K. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009;14:1039-43.
26. Niemi M, Backman JT, et al. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003;42:819-50. (Pubitemid 36995083)
27. Nieminen TH, Hagelberg NM, et al. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone. Anesthesiology 2009;110:1371-8.
28. Park JY, Kim KA, Kang MH. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004;75:157-62.
29. Perlrot J, et al. Adjunctive use of rifampin for the treatment of Staphylococcus aureus infections - A systematic review of the literature. Arch Intern Med 2008;168:805-19.
30. Reinhart K, Brunkhorst FM, et al. Prävention, Diagnose, Therapie und Nachsorge der Sepsis. GMS German Medical Science 2010, Vol. 8, ISSN 1612-3174, http://www.egms.de/static/de/journals/gms/2010-8/000103. shtml.
31. Soars MG, Petullo DM, Eckstein JA. An assessment of udp- glucuronosyltransferase induction using primary human hepatocytes. Drug Metab Dispos 2004;32:140-8. (Pubitemid 38112546)
32. Strayhorn VA, Baciewicz AM, et al. Update on rifampin drug interactions. Arch Intern Med 1997;157:2453-8. (Pubitemid 27517980)
33. Tapaninen T, Neuvonen PJ, Niemi M. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010;66:497-502.
34. Tirana RG, Lee W, Leake BF. The orphan nuclear receptor HNF4alpha determines PXR- and CAR-mediated xenobiotic induction of CYP3A4. Nat Med 2003;9:220-4. (Pubitemid 36227725)
35. Venkatesan K. Pharmacokinetic drug interactions with rifampicin. Clin Pharmacokinet 1992;22:47-65.
36. Wehrli W. Rifampin: mechanisms of action and resistance. Rev Infect Dis 1983;5(Suppl 3):S407-11.